Shanghai Rendu Biotechnology Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 78.66 million compared to CNY 161.73 million a year ago. Revenue was CNY 80.03 million compared to CNY 169.66 million a year ago.

Net loss was CNY 10.19 million compared to net income of CNY 21.92 million a year ago. Basic loss per share from continuing operations was CNY 0.25 compared to basic earnings per share from continuing operations of CNY 0.63 a year ago. Diluted loss per share from continuing operations was CNY 0.25 compared to diluted earnings per share from continuing operations of CNY 0.62 a year ago.